Stocktoria
C4 Therapeutics, Inc. CCCC
C4 Therapeutics, Inc. (CCCC) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $35.9M at a -292.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.627 |
| Retained earnings / assets | -2.057 |
| EBIT / assets | -0.321 |
| Equity / liabilities | 2.504 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CCCC | C4 Therapeutics, Inc. | 3/9 | -2.12 | — | +1% |
| XFOR | X4 Pharmaceuticals, Inc | 3/9 | -1.48 | — | — |
| DTIL | PRECISION BIOSCIENCES INC | 1/9 | -7.2 | — | -50.1% |
| KYMR | Kymera Therapeutics, Inc. | 3/9 | 9.79 | — | -16.7% |
| SGMO | SANGAMO THERAPEUTICS, INC | 2/9 | — | — | -31.6% |
| VYGR | Voyager Therapeutics, Inc. | 1/9 | -1.03 | — | -49.5% |
| EDIT | Editas Medicine, Inc. | 1/9 | — | — | +25.4% |
About C4 Therapeutics, Inc.
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
FAQ
Is CCCC financially healthy?
C4 Therapeutics, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does CCCC pay a dividend?
No, C4 Therapeutics, Inc. does not currently pay a dividend.
How profitable is CCCC?
In FY2025, C4 Therapeutics, Inc. had a net margin of -292.1% and a return on equity of -40.9%.
What is the analyst price target for CCCC?
The average Wall-Street price target for C4 Therapeutics, Inc. is $13.33, about 241.9% above the recent price, from 6 analysts (consensus: strong buy).
Is CCCC a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on C4 Therapeutics, Inc.: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.